Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Juvenile Diabetes Research Foundation (JDRF) and Amylin Pharmaceuticals have signed a research pact to conduct series of clinical trials for evaluating the feasibility of mixing pramlintide with insulin for the treatment of type 2 diabetes.
Subscribe to our email newsletter
Under the pact, both the companies will evaluate whether a fixed ratio of pramlintide and insulin can effectively help treat type 1 diabetes.
The program will also evaluate the optimal pramlintide: insulin dose ratios, and determine whether delivering pramlintide and insulin in this fixed ratio, can improve glucose control and optimize treatment of type 1 diabetes compared with insulin alone.
JDRF Treatment Therapies assistant vice president Aaron Kowalski said the study of this combination therapy is exciting because, if successful, it could potentially help patients achieve tighter glucose control without increasing treatment complexity.
"Successfully co-formulating pramlintide and insulin could potentially help people living with type 1 diabetes to better, and more conveniently, control their disease," Kowalski said.